Abstract | RATIONALE AND OBJECTIVES: A new hepatobiliary gadolinium chelate, gadolinium ( Gd) 2,5-BPA-DO3A, was compared in two animal species with Gd HP-DO3A ( gadoteridol), a clinically approved extracellular contrast agent, and Gd Cy2-DOTA, a second hepatobiliary chelate in preclinical development. The ligand in Gd 2,5-BPA-DO3A is macrocyclic in nature, as opposed to the linear structure of Gd DTPA. Gadolinium 2,5-BPA-DO3A was evaluated on magnetic resonance imaging at 1.5 T, examining specifically liver parenchymal enhancement and lesion delineation, the latter in metastatic disease. METHODS:
Gadolinium 2,5-BPA-DO3A was evaluated in five normal rhesus monkeys and four New Zealand White rabbits with implanted VX-2 liver tumors. These studies were compared with magnetic resonance exams in the same animals using Gd HP-DO3A and Gd Cy2-DOTA. A contrast dose of 0.1 mmol/kg intravenous was employed in each instance, with the sequence of administration (for the three agents) randomized and at least 72 hours between injections. Spin echo breathhold T1-weighted scans were obtained before and at multiple times after contrast administration. Postcontrast scans were acquired from 1 to 60 minutes after injection in the monkeys and from 1 to 240 minutes in the rabbits. RESULTS: Enhancement of normal liver parenchyma was markedly superior with Gd 2,5-BPA-DO3A compared with Gd HP-DO3A and Gd Cy2-DOTA in both monkeys and rabbits. At 2 and 60 minutes after contrast administration, the liver signal intensity in the monkey was 452 +/- 56 and 440 +/- 69 with Gd 2,5-BPA-DO3A compared with 295 +/- 34 and 256 +/- 38 with Gd HP-DO3A. The difference between agents was statistically significant at all postcontrast time points in the rhesus monkey. Excretion of contrast into the gall bladder was consistently observed after Gd 2,5-BPA-DO3A injection in both animal species. Maximum lesion conspicuity occurred in the rabbit at 45 minutes after Gd 2,5-BPA-DO3A administration. At 45 minutes postinjection, liver-lesion contrast was 0.60 +/- 0.15 with Gd 2,5-BPA-DO3A, 0.35 +/- 0.11 with Gd Cy2-DOTA, and 0.12 +/- 0.04 with Gd HP-DO3A, with the differences between agents being statistically significant. CONCLUSIONS:
|
Authors | V M Runge, J W Wells, N M Williams |
Journal | Investigative radiology
(Invest Radiol)
Vol. 31
Issue 1
Pg. 11-6
(Jan 1996)
ISSN: 0020-9996 [Print] United States |
PMID | 8850360
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- Contrast Media
- Heterocyclic Compounds
- Organometallic Compounds
- gadolinium 2,5-BPA-DO3A
- gadolinium Cy(2)DOTA
- gadoteridol
- Gadolinium
|
Topics |
- Animals
- Carcinoma
(diagnosis, pathology, secondary)
- Contrast Media
(administration & dosage, pharmacokinetics)
- Gadolinium
(administration & dosage, pharmacokinetics)
- Gallbladder
(metabolism)
- Heterocyclic Compounds
(administration & dosage, pharmacokinetics)
- Image Enhancement
- Injections, Intravenous
- Liver
(anatomy & histology)
- Liver Neoplasms, Experimental
(diagnosis, pathology, secondary)
- Macaca mulatta
- Magnetic Resonance Imaging
- Neoplasm Transplantation
- Organometallic Compounds
(administration & dosage, pharmacokinetics)
- Rabbits
- Time Factors
|